Phase I Trial HIPEC With Nal-irinotecan
Conditions: Peritoneal Cancer; Pseudomyxoma Peritonei; Mucinous Adenocarcinoma; Mucinous Tumor; Colorectal Cancer; Gastric Cancer; Primary Peritoneal Carcinoma; Mesothelioma Intervention: Drug: nanoliposomal irinotecan Sponsors: Stony Brook University; University of Kentucky; University of San Diego Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Adenocarcinoma | Asbestosis | Cancer | Cancer & Oncology | Carcinoma | Gastroenterology | Mesothelioma | Nanotechnology | Research